
HB 134 – Maryland
Status: Inactive / DeadYear Introduced: 2020
Link: http://mgaleg.maryland.gov/mgawebsite/Legislation/Details/HB0134?ys=2020RS
Health Insurance – Prescription Insulin Drugs – Limits on Copayment and Coinsurance. Requiring certain insurers, nonprofit health service plans, and health maintenance organizations to limit the cumulative amount a covered individual is required to pay on copayment or coinsurance for a covered prescription insulin drug to no more than $100, regardless of the amount or type of insulin needed to fill the covered individual’s prescriptions; applying the Act to all policies, contracts, and health benefit plans issued, delivered, or renewed in the State on or after January 1, 2021; etc.
Return to Database Search
© 2018- The SLIHCQ Database. Initial funding for this project was provided by the Robert Wood Johnson Foundation. The views expressed here do not necessarily reflect the views of the Foundation.
Associated Litigation:
No items found